Chlamydia mRNA Vaccine
Phase 1/2Active 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chlamydia Trachomatis Immunization
Conditions
Chlamydia Trachomatis Immunization
Trial Timeline
Mar 27, 2025 → Jan 3, 2028
NCT ID
NCT06891417About Chlamydia mRNA Vaccine
Chlamydia mRNA Vaccine is a phase 1/2 stage product being developed by Sanofi for Chlamydia Trachomatis Immunization. The current trial status is active. This product is registered under clinical trial identifier NCT06891417. Target conditions include Chlamydia Trachomatis Immunization.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06891417 | Phase 1/2 | Active |
Competing Products
1 competing product in Chlamydia Trachomatis Immunization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EVO100 + Placebo | Evofem Biosciences | Phase 2/3 | 57 |